Aclaris Therapeutics
ACRS
126 hedge funds and large institutions have $1.02B invested in Aclaris Therapeutics in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 22 closing their positions.
188% more call options, than puts
Call options by funds: $2.33M | Put options by funds: $807K
42% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 36
4% more capital invested
Capital invested by funds: $980M → $1.02B (+$42.5M)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 128 → 126 (-2)
1.93% less ownership
Funds ownership: 94.68% → 92.76% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.6M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$9.53M |
| 3 |
Holocene Advisors
New York
|
+$8.93M |
| 4 |
BlackRock
New York
|
+$8.81M |
| 5 |
CC
Commodore Capital
New York
|
+$8.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$14.8M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.9M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.02M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.95M |
| 5 |
Renaissance Technologies
New York
|
-$6.59M |
ACRS Hedge Fund Activity: Q3 2021 in Review
126 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2021, worth a combined $1.02B — up 4.3% from $980M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ACRS and 21 opened new positions — a net loss of 1 holder — while 36 trimmed existing stakes and 51 added.
The largest buyer was Wellington Management Group, adding an estimated $11.6M. The largest seller was Adage Capital Partners, cutting an estimated $14.8M.
- 126 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2021, down from 128 in Q2 2021.
- Funds reported $1.02B of Aclaris Therapeutics stock for Q3 2021, up 4.3% quarter-over-quarter.
- 21 funds opened new Aclaris Therapeutics positions in Q3 2021 and 22 closed out, a net change of -1 holder.
- The largest Aclaris Therapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $11.6M added.
- The largest Aclaris Therapeutics seller in Q3 2021 was Adage Capital Partners, an estimated $14.8M sold.
Based on aggregated 13F filings for Q3 2021.